Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
- 643 Downloads
Mounting evidence suggests that RAF-mediated MEK activation plays a crucial role in paradox MAPK (re)activation, leading to resistance and therapeutic failure with agents hitting a single step along the MAPK cascade.
We examined the molecular and functional effects of single and combined BRAF (dabrafenib), pan-RAF (RAF265), MEK (trametinib) and EGFR/HER2 (lapatinib) inhibition, using Western Blot and conservative isobologram analysis to assess functional synergism, and explored genetic determinants of synergistic interactions. Immunoprecipitation based assays were used to detect the interaction between BRAF and CRAF. The Mann-Whitney U test was used for comparing quantitative variables.
Here we demonstrated that a combination of MEK and BRAF inhibitors overcomes paradoxical MAPK activation (induced by BRAF inhibitors) in BRAF-wt/RAS-mut NSCLC and PDAC in vitro. This results in growth inhibitory synergism, both in vitro and in vivo, in the majority (65%) of the cellular models analyzed, encompassing cell lines and patient-derived cancer stem cells and organoids. However, RAS mutational status is not the sole determinant of functional synergism between RAF and MEK inhibitors, as demonstrated in KRAS isogenic tumor cell line models. Moreover, in EGFR-driven contexts, paradoxical MAPK (re)activation in response to selective BRAF inhibition was dependent on EGFR family signaling and could be offset by simultaneous EGFR/HER-2 blockade.
Overall, our data indicate that RAF inhibition-induced paradoxical MAPK activation could be exploited for therapeutic purposes by simultaneously targeting both RAF and MEK (and potentially EGFR family members) in appropriate molecular contexts. KRAS mutation per se does not effectively predict therapeutic synergism and other biomarkers need to be developed to identify patients potentially deriving benefit from combined BRAF/MEK targeting.
KeywordsMAPK BRAF MEK Combination therapy Paradoxical effect
Protein kinase B
American Type Culture Collection
Epidermal Growth Factor Receptor
Human Epidermal Growth Factor Receptor 2
50% of Cell growth Inhibition
Lung Cancer Stem Cells
Mitogen-Activated Protein Kinase
Mitogen-activated protein kinase kinase
mammalian Target of Rapamycin
Non-Small Cell Lung Cancer
Pancreatic Ductal AdenoCarcinoma
Rapidly Accelerated Fibrosarcoma
Receptor Tyrosine Kinase
The Mitogen-Activated Protein Kinase (MAPK) pathway is a key signaling pathway involved in the physiologic regulation of cell growth, survival, differentiation, apoptosis and migration . Aberrant activation of the MAPK pathway has been implicated in the pathogenesis of many human diseases, including cancer, in which MAPK activation may stem from either genetic aberrations targeting RAS, B Rapidly Accelerated Fibrosarcoma (BRAF), or Mitogen-activated protein kinase kinase (MEK) directly or dysregulation of upstream acting Receptor Tyrosine Kinases (RTK) [2, 3]. MAPK activation is finely regulated at different levels; moreover, in addition to “inter-pathway” crosstalks operating at multiple levels between MAPK and other signaling cascades (e.g. PhosphoInositide3-Kinase (PI3K)/ Protein kinase B (AKT)/ mammalian Target of Rapamycin (mTOR) [4, 5]) “intra-pathway” feedback loops regulate Extracellular-signal-Regulated Kinase (ERK) activity through phosphorylation, intracellular localization, and complex formation [6, 7, 8]. As a result, inhibition of a single step (either BRAF or MEK) of the cascade has met with limited clinical success , presumably because of the interruption of negative feedback loops leading to downstream pathway (re)activation. Indeed, in some genetic contexts, selective BRAF inhibition has been linked to paradoxical MAPK activation, a phenomenon attributed to the ability of BRAF inhibitors to activate RAF signaling by promoting CRAF-BRAF dimerization, in BRAF wild-type cells [10, 11, 12].
Over the past few years, a vertical combination of BRAF and MEK inhibitors (dabrafenib/trametinib or vemurafenib/cobimetinib) has demonstrated striking clinical efficacy and has become a standard of care in patients with BRAF-mut melanoma and lung cancer [13, 14, 15, 16], although the molecular mechanisms by which combined BRAF/MEK inhibition results in synergistic anti-tumor activity are still not completely clear and the same combinations have not met with the same therapeutic success in other BRAF-mut cancer type of different histological origin . On the other hand, RAF activation has been shown to be crucial to RAS-mediated transformation and its inhibition, by either isoform-selective or non-selective inhibitors, appears to be essential for effective downstream MEK/ERK inhibition  and strikingly synergizes with MEK inhibition in controlling tumor growth and overcoming resistance, particularly in KRAS mutation-driven contexts [19, 20].
Here we analyzed the molecular and functional effects of combined BRAF/MEK inhibition in cell line and patient-derived preclinical models of Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Ductal AdenoCarcinoma (PDAC) and found that selective BRAF inhibition causes paradoxical MAPK activation that could be reversed by simultaneous MEK blockade; functionally, a combination of dabrafenib (selective BRAF inhibitor) and trametinib (selective MEK inhibitor) achieved strikingly synergistic in vitro tumor growth inhibition in a proportion of the models assessed; however, RAS mutational status appears not to be sole determinant of functional synergism between RAF and MEK inhibitors. Indeed, in Epidermal Growth Factor Receptor (EGFR)-family driven models, paradoxical MAPK reactivation appears to be sustained by RTK signaling and may be reversed by EGFR/Human Epidermal Growth Factor Receptor 2 (HER2)- blockade.
HCC827 cell lines were obtained from the American Type Culture Collection (ATCC). Isogenic cells lines HCT116 (HK2–6 and HKE-3) were kindly provided by Dr. Shirasawa and performed by gene targeting technique ; NCI-H1299 cell lines and relative clones (H1299 K4, D2, C2, V9) were kindly donated by Dr. Broggini . Lung Cancer Stem Cells (LCSC) were generated in vitro as previously reported [23, 24].
Cell lines were routinely maintained in RPMI 1640 or DMEM medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and antibiotics in a humidified atmosphere with 5% CO2 at 37 °C.
Drugs treatment and cell proliferation assay
Trametinib (GSK1120212), dabrafenib (GSK2118436) and lapatinib (Tyverb) were kindly provided by GlaxoSmithKline (Brentford, Middlesex, UK). Trametinib and lapatinib were dissolved in DMSO as a 1 mM stock solution and stored at − 20 °C, dabrafenib was dissolved in DMSO as a 10 mM stock solution and stored at − 20 °C. RAF265 (CHIR-265, R265) was obtained from Novartis Pharma (Basel, Switzerland) and dissolved in DMSO as a 10 mM stock solution and stored at − 20 °C. The final concentration of both drugs was obtained by dilution with culture medium. Effects on cell growth in response to different treatments were monitored by Crystal Violet assay . For Crystal Violet assay, a fixed number of tumor cells were dispensed into 24-wells (NEST Biotechnology), and the following day cells were treated at indicated concentrations of drugs .
Procedures relative to animal use and care were authorized and certified by Italian Minister of Health (decree n. 67/97A, protocol 2560/97, Rome Health Service Unit). Regina Elena National Cancer Institute and animal care Unit approved the procedures involving animals (species, quality and number of animals, discomfort/distress/pain of animals, anaesthesia and euthanasia).
5 × 106 MiaPaCa2 cells were intramuscularly injected into immunodeficient athymic mice (6–8 week-old female). Four groups of animals with similar tumor volume were created when the tumors reached palpability. The following treatments were administered for two weeks: 1) daily vehicle administration; 2) daily oral administration with 0.2 mg/Kg trametinib; 3) daily oral administration with 30 mg/Kg dabrafenib; 4) combination treatment (0.2 mg/Kg trametinib + 30 mg/Kg dabrafenib). 6 animals composed each group. Tumor weight (in mg) was estimated daily based on the measurement of the longest perpendicular diameters, as previously described . Animals were also daily monitored for food consumption, body-weight, and behavior. Animals were sacrificed 27 days after tumor cell injection. Differences between treatment groups were analyzed by 2-tailed Student’s t test for unpaired samples; statistical significance was set at p < 0.05.
Human pancreatic tumor and normal organoid culture: Isolation, culture and proliferation assay
Human neoplastic organoid cultures were established from resected PDAC specimens. Specimens from pancreatic resections were digested enzymatically with collagenase/dispase dissociation and then plated in Matrigel to generate pancreas organoid cultures, in human complete medium . PDAC organoids were then maintained in human complete medium. For the 50% of cell growth inhibition (IC50) analysis, organoids were dissociated into single cells by first triturating them in media through a fire-polished glass pipette, and then by enzymatic dissociation with 2 mg/ml dispase dissolved in TrypLE (Life Technologies). Cells were counted and diluted to 10 cells/μl in a mixture of complete media, Rho Kinase inhibitor Y-27632 (10.5 μM final concentration, Sigma) and Growth factor-reduced Matrigel (GFR-Matrigel, 10% final concentration). 100 μl of this mixture (1000 cells/well) was plated in 96-well plates (Nunc), whose wells had been previously coated with a bed of GFR-Matrigel to prevent attachment of the cells to the bottom of the plate. Cell viability in response to the different drugs was measured using the CellTiter-Glo assay (Promega Corporation) and Synergy 4 reader (Biotek).
Sanger sequencing for cell lines and organoids
DNA was extracted from cell lines using the QIAamp DNA mini kit (Qiagen) and quantified with the Nanodrop Spectrophotometer (Thermo). Primers for amplification and sequencing of exon 2 of the KRAS gene (Fw: aggcctgctgaaaatgactgaata and Rw: ctgtatcaaagaatggtcctgcac) and of exon 15 of the BRAF gene (Fw: tcataatgcttgctctgatagga and Rv: ggccaaaaatttaatcagtgga), PCR products were purified using the Nucleospin kit and sequenced by capillary electrophoresis using the BigDye Terminator v3.1 cycle sequencing kit on 3130 Genetic Analyzer (Applied Biosystem). Sequence traces were analyzed using the Clustal W program (https://embnet.vital-it.ch/software/ClustalW.html). For organoids Sanger Sequencing see https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334572/#SD15 .
Western blot (WB) analysis
For immunoprecipitation cells were rinsed three times with ice-cold PBS, scraped with CHAPS buffer (0.3% CHAPS; 40 mM HEPES; 120 mM NaCl; 1 mM EDTA; 50 mM NaF; 10 mM Glycerol phosphate and 10X pyrophosphate) and lysed by incubation on ice for 30 min after 4 h of treatments. RAF-1 antibody agarose conjugate (Santa Cruz Biotechnology) was used as primary Abs and incubated over night at 4 °C. The immunoprecipitates were collected by centrifugation at 5000 rpm for 5 min at 4 °C and after 2 wash in CHAPS buffer re-suspended in 20 μl of the same buffer and Ladder buffer 4X. The immune complexes were analyzed by Western blot analyses with mouse anti-CRAF antibody. Protein lysates were also subjected to Western blot analyses with BRAF, CRAF and β-actin antibodies. Image detection was performed with Amersham Hyperfilm ECL (Amersham; Fig. 1; Additional file 1: Figure S1).
The Mann-Whitney U test was used for comparing quantitative variables. Results with two-tailed P values < 0.05 were judged to be statistically significant. Statistical analysis was performed with SPSS 21.0 software (SPSS, Chicago, IL). Synergism, additivity, and antagonism were assessed by isobologram analysis with a fixed-ratio experimental design using the Chou-Talalay method . Results were analyzed with the Calcusyn software (Biosoft, Cambridge, United Kingdom) and Combination Index (CI) were appropriately derived. By this method, an average CI at the ED50, ED75, and ED90 < 1 indicates synergism, = 1 indicates additivity, and > 1 indicates antagonism, respectively. For organoids analysis, IC50 and the CI were calculated according to the Chou-Talalay method using Compusyn. All the experimental methods were performed in accordance with the institutional National and International guidelines and regulations.
Selective BRAF inhibition causes paradoxical ERK activation in BRAF-wt/KRAS-mut contexts
First, we investigated the effects of BRAF and/or MEK inhibition (using dabrafenib and trametinib, respectively) on MAPK pathway activation in KRAS-mut lung and pancreatic cancer cell lines (Additional file 1: Table S1). In both A549 (KRAS-mut/BRAF-wt lung adenocarcinoma) and MiaPaCa2 (KRAS-mut/BRAF-wt PDAC) exposure to the BRAF-selective inhibitor dabrafenib for 4 h resulted in the dose-dependent phosphorylation of MEK, ERK and p90RSK, revealing a paradoxical MAPK activation (Fig. 1a); such paradoxical activation was maintained or increased up to 72 h (data not shown). Results in terms of MAPK pathway activation were more variable in response to the pan-RAF inhibitor RAF265; however, paradoxical ERK activation was observed in both cell lines, but only at low/intermediate concentrations (0.1 to 2.5 μM), with relatively little changes occurring at the level of MEK and p90RSK phosphorylation (Fig. 1b). Single-agent treatment with the MEK inhibitor trametinib efficiently inhibited ERK phosphorylation (Fig. 1c-d) and strikingly reduced RAF inhibition-induced ERK and p90RSK phosphorylation, thereby blunting the paradoxical effect (Fig. 1c-d). Similar results were obtained in all the KRAS-mut lung (A427) and pancreatic (PACA44, HPAFII, L3.6pl and PANC1) cancer cell lines analyzed. Paradoxical activation of MEK/ERK signaling following BRAF inhibition has been primarily ascribed to the formation of BRAF/CRAF heterodimers that stimulate ERK signaling . To explore this possibility in our system, we analyzed the formation of BRAF/CRAF complexes in response to either dabrafenib or RAF265. As assessed by IP/WB, both RAF inhibitors caused BRAF/CRAF heterodimer formation in A549 cells (Fig. 1e); similar results were obtained in the KRAS-mut pancreatic cancer cell line HPAFII (Additional file 1: Figure S1).
Functional effects of simultaneous RAF and MEK inhibition in BRAF-wt/RAS-Mut contexts
Effects of combined BRAF/MEK inhibition in patient-derived lung CSC and pancreatic cancer organoids
Efficacy of the combination of trametinib and dabrafenib in isogenic cell lines with different KRAS mutational background
Potential role of RTKs in paradoxical MAPK activation
In this study, we investigated the potential of a combinatorial treatment with small molecules targeting key components of the MAPK pathway, namely BRAF and MEK, in KRAS-mut NSCLC and PDAC. In line with current literature, selective BRAF blockade resulted in paradoxical downstream MAPK activation, which was reversed by simultaneous MEK inhibition. In a consistent proportion (21/32, 65%) of the models examined (both cell lines and patient-derived lung CSC and PDAC organoids), the “vertical” combination of dabrafenib and trametinib (targeting BRAF and MEK) resulted in synergistic tumor growth inhibition in vitro, mostly due to greater inhibition of proliferation achieved with combined treatment. In the MiaPaCa2 xenograft model, combined dabrafenib and trametinib also resulted in significantly greater tumor growth inhibition in vivo, as compared to each agent alone. Pan-RAF inhibitors (such as RAF265) had more variable effects in terms of both paradoxical MAPK activation and functional synergism with MEK inhibitors. Although the combination appeared to be synergistic in the majority of KRAS-mut cell lines, no definitive mechanistic association between KRAS mutational status and functional synergism with combined BRAF/MEK inhibition was found, supporting the idea that RAS mutational status is not the sole determinant of functional synergism between RAF and MEK inhibitors. Indeed, in KRAS-wt contexts, paradoxical MAPK activation in response to BRAF inhibition may still occur and appears to be mediated by upstream signaling through RTKs (namely EGFR family members).
The majority of PDAC (~ 90%) and a high proportion (25–40%) of NSCLC harbor oncogenic activation of KRAS [28, 29, 30, 31], which have been demonstrated to be necessary to both initiate and maintain tumorigenesis . Mutant KRAS engages several downstream pathways, including the MAPK signaling cascade, to execute its oncogenic program . While RAS mutations are an established resistance factor to an array of targeted agents [33, 34], clinical attempts at targeting RAS activity, either directly or by targeting common downstream effectors, have failed so far . One appealing strategy would be to target MAPK activation downstream of RAS: indeed, RAF proteins have been shown to be indispensable for RAS-dependent transformation and progression in several cancer models [36, 37, 38]; moreover, early evidence has suggested that the presence of KRAS mutations might portend sensitivity to MEK inhibitors [39, 40, 41, 42, 43, 44, 45]. However, clinical translation of single-step RAF or MEK inhibition in cancer has been hampered by complex feedback mechanisms that are not only able to reactivate targeted pathways following treatment [18, 46], but also specifically and differentially operate in different tumor genetic backgrounds. According to currently accepted mechanistic models, we show here that exposure of KRAS-mutant cells (including lung CSC and PDAC organoids) to BRAF-selective inhibitors results in the paradoxical activation of the MEK/ERK module, due to the formation of CRAF/BRAF dimers, as previously reported [10, 11, 12]. Conversely, in BRAFV600E melanomas no BRAF/CRAF heterodimer formation was observed and both BRAF- and MEK-selective inhibitors efficiently shut down ERK activation (Cesta Incani et al., 2018, manuscript in preparation), even when used as single agents. As a consequence, simultaneous RAF/MEK inhibition has a strong mechanistic rationale in BRAF-wt (and particularly in KRAS-mut) genetic contexts [18, 19, 20]. Our findings do support this concept, as striking growth-inhibitory synergism was observed with dabrafenib and trametinib in the majority of NSCLC and PDAC models tested (both cell lines and, most importantly, patient-derived lung CSC and PDAC organoids). However, a few important points remain to be clarified: 1) whether selective or broad-spectrum RAF-isoform inhibition might be more advantageous in combination with MEK inhibitors; 2) the role of KRAS-mut as a potential selection biomarker for the “vertical” RAF/MEK inhibitor combination.
Literature data suggest that CRAF inhibition is crucial to enable MEK inhibitors to effectively inhibit downstream signaling to ERK1/2  and that pan-RAF inhibitors could more potently synergize with MEK inhibitors, as compared with BRAF-selective inhibitors . In our hands, the pan-RAF inhibitor RAF265 had more variable effects, as compared to the BRAF-selective inhibitor dabrafenib, on both paradoxical ERK activation and growth-inhibitory synergism; such discrepancies may be due to several different reasons, including the different dynamics and dose-dependency of inhibition of individual RAF isoforms, cellular ATP levels [10, 47], the specific genetic background of the models tested, and the specific site of action of the MEK inhibitors being combined . Overall, while the general strategy of inhibiting both RAF and MEK along the MAPK cascade appears to be promising even outside the clinically validated BRAF-mut genetic context (see also earlier work conducted by our group in leukemia models, ), the optimal selection of agents/mechanisms of action of RAF and MEK inhibitors to be combined remains to be addressed, taking into account the clinical tolerability profile of individual agents/combinations.
Paradoxical MAPK pathway activation in response to BRAF-selective inhibitors was initially closely linked to RAS mutational status, in fact this effect was absent in cells with wild-type RAS, while it was restored after the introduction of an oncogenic RAS [49, 50]. Together with evidence that “vertical” RAF/MEK blockade was synthetically lethal in KRAS-mut contexts , such background prompted us to select NSCLC and PDAC, two diseases where KRAS mutations are frequent and bear important clinical consequences, as the main target of our analysis. However, synergism analysis across the entire set of cellular models analyzed displayed no significant correlation between RAS mutational status and synergistic interactions between dabrafenib and trametinib. Such observation was mechanistically corroborated by evidence that pharmacological interactions between BRAF and MEK inhibitors were not substantially modified in isogenic cellular models of lung and colorectal cancer differing for KRAS status. This observation is consistent with evidence that paradoxical MAPK activation in response to BRAF inhibition also occurs in KRAS-wt/BRAF-wt genetic contexts (as shown in this report and in ) and supports the idea that RAS mutational status is not the sole determinant of combined treatment outcome. In that respect, complexities in evaluating the role of RAS mutations in driving different tumor phenotypes are highlighted by recent evidence showing that distinct evolutionary routes, licensed by defined allelic states and/or combinations of hallmark tumor suppressor alterations (Cdkn2a, Trp53, Tgfβ-pathway), direct variations of oncogenic RAS dosage gain, to drive the early progression of PDAC and shape its downstream biology .
RTKs (and EGFR family members in particular) are a likely candidate to mediate paradoxical MAPK activation in response to inhibition of a single step of the cascade; indeed, EGFR family-mediated (re)activation of either the MAPK pathway itself or other crosstalking pathways (such as the PI3K/AKT axis) has been described in several cancer models, with or without and underlying BRAF or KRAS mutation [52, 53]. Consistent with these data, here we show that in tumor cellular contexts that are highly dependent on EGFR family signaling, such as the HER2-amplified (Calu3) and EGFR-mutant (HCC827) NSCLC cell lines, BRAF inhibition paradoxically reactivated the MAPK pathway in an EGFR/HER2-dependent manner; interestingly, we observed a similar EGFR family feedback activation in response to either BRAF or MEK inhibition in colorectal cancer cell lines and patient-derived cancer stem cells  (Bazzichetto C., unpublished results). In this specific context, EGFR/HER2 inhibition by lapatinib was able to shut down paradoxical MAPK hyperactivation in response to dabrafenib, whereas in KRAS-mutant cell lines, in which the need for EGFR family activation is bypassed by constitutively active RAS, lapatinib was ineffective in that respect. Based on this evidence, co-targeting of EGFR family members upstream and MAPK signal transducers (RAF, MEK) downstream has been proposed as a promising therapeutic strategy [52, 54, 55] and, in part, validated clinically in BRAF-mut CRC [45, 56, 57]. However, we did not observe growth-inhibitory synergism in vitro with combined lapatinib and either dabrafenib or trametinib in HER2-amplified or EGFR-mutant NSCLC models. This might be due to the high intrinsic sensitivity of these models to lapatinib: accordingly, recent data show that, in colorectal cancer models, combined blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies and results in therapeutic synergism only once resistance to anti-EGFR agents has ensued [54, 58], suggesting that in highly sensitive models the right setting to apply combinatorial strategies might be treatment-resistant disease.
This work was supported in part by grants from the Italian Association for Cancer Research (AIRC) (Michele Milella, IG 14362; Vincenzo Corbo, IG 18718; Donatella Del Bufalo, IG 18560), Special Program Molecular Clinical Oncology 5 per mille (Aldo Scarpa, 12182), and EU-CamPac 602783 (Aldo Scarpa). Fabiana Conciatori is a PhD student at the Doctoral School of Oncology of the University of Rome “La Sapienza” and Chiara Bazzichetto is a PhD student at the Doctoral School of Immunological, Hematological and Rheumatological Sciences. Anais Del Curatolo was supported by a fellowship award of the AIRC (19404, 20872).
L.C. and M.M. contributed to conception and design of all the experiments, supervised data acquisition and analysis, and wrote the manuscript; A.D.C. and F.C. performed experiments, contributed to data acquisition, analysis and interpretation of the results, and critically revised the manuscript; C.B., U.C.I. and I.F. performed experiments and contributed to data acquisition and analysis; V.C. and S.D. performed organoids experiments and critically revised the manuscript; T.D.L. and D.D.B. performed animal study and critically revised the manuscript; A.E., G.S. and R.D.M. generated CSC, performed and analyzed CSC experiments; I.S. performed all statistical analyses; A.S., M.B., M.M., S.S. and F.C. provided critical reagents, contributed to conception and critically revised the manuscript. All authors reviewed and gave final approval.
Ethics approval and consent to participate
LCSC were derived from tumor samples obtained in accordance with procedures and protocols approved by the internal review board of the Sant’Andrea Hospital, University of Rome “La Sapienza”. All patients signed an informed consent form. The use of such material was formally approved by the Ethical Committee/Institutional Review Board of the Regina Elena National Cancer Institute to the commencement of the study.
Pancreatic cancer tissues and adjacent normal pancreas were obtained from patients undergoing surgical resection at the University and Hospital Trust of Verona. All human experiments were approved by the Integrated University Hospital Trust Ethics Committee (approval number 1885). Written informed consent from the donors for research use of tissue in this study was obtained prior to acquisition of the specimen. Samples were confirmed to be tumor or normal based on pathological assessment.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 8.Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Falcone I, Sette G, Bergamo P, et al. The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. J Mol Med (Berl). 2012;90:667–79.CrossRefGoogle Scholar
- 13.Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444–51.CrossRefPubMedGoogle Scholar
- 16.Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland A, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18:1307–16.CrossRefPubMedGoogle Scholar
- 26.Milella M, Trisciuoglio D, Bruno T, Ciuffreda L, Mottolese M, Cianciulli A, Cognetti F, Zangemeister-Wittke U, Del Bufalo D, Zupi G. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells. Clin Cancer Res. 2004;10:7747–56.CrossRefPubMedGoogle Scholar
- 31.Sherwood J, Dearden S, Ratcliffe M, Walker J. Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review. J Exp Clin Cancer Res. 2015;34:92.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9:962–72.CrossRefPubMedGoogle Scholar
- 44.Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang J, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res. 2011;17:989–1000.CrossRefPubMedGoogle Scholar
- 46.Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell. 2012;22:668–82.CrossRefPubMedPubMedCentralGoogle Scholar
- 48.Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, et al. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. J Mol Med (Berl). 2012;90:1133–44.CrossRefGoogle Scholar
- 50.Packer LM, Rana S, Hayward R, O'Hare T, Eide CA, Rebocho A, Heidorn S, Zabriskie MS, Niculescu-Duvaz I, Druker BJ, et al. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell. 2011;20:715–27.CrossRefPubMedPubMedCentralGoogle Scholar
- 53.Fattore L, Malpicci D, Marra E, Belleudi F, Noto A, De Vitis C, Pisanu ME, Coluccia P, Camerlingo R, Roscilli G, et al. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. Oncotarget. 2015;6:24823–41.CrossRefPubMedPubMedCentralGoogle Scholar
- 54.Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med. 2014;6:224ra226.CrossRefGoogle Scholar
- 56.Corcoran RBAT, Yoshino T, Bendell JC, Atreva CE, Schellens JHM, Ducreux MP, Mcree A, Siena S, Middleton G, et al. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumubab (P) in patients (pts) with BRAF V600E-mutated (BRAFm) metastatic colorectal cancer (mCRC). In ESMO. 2016;27(6):149–206. https://doi.org/10.1093/annonc/mdw370.
- 57.Van Cutsem ECPJ, Huijberts S, Yaeger R, Schellens JHM, Elez E, Tabernero J, Fakih M, Montagut C, Peeters M, et al. BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): efficacy and tumor markers. In: ASCO, vol. 36: J Clin Oncol; 2018.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.